Capital Com MENA Securities Trading LLC is regulated by the Capital Market Authority.
Open platformOpen platform

4D Molecular Therapeutics Q3 2026 net loss widens 37% to $78.06 million

By Public Technologies
  • 4D Molecular Therapeutics’ third-quarter 2026 net loss widened 37% year over year to $78.06 million.
  • Collaboration and license revenue rose to $4.15 million, primarily due to clinical trial cost sharing and reimbursement from Otsuka.
  • Cash, cash equivalents and marketable securities totaled $375.03 million at September 30; funding runway extends into the second half of 2028.
  • Topline results from wet AMD trials 4FRONT-1 and 4FRONT-2 are expected in Q2 2027 and the second half of 2027, respectively.
  • The company initiated the global Phase 3 4SIGHT trial of 4D-150 in diabetic macular edema.


Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. 4D Molecular Therapeutics Inc. published the original content used to generate this news brief via GlobeNewswire (Ref. ID: 202611121605PRIMZONEFULLFEED9876738) on November 12, 2026, and is solely responsible for the information contained therein.

Capital.com is an execution-only brokerage platform and the content provided on the Capital.com website is intended for informational purposes only and should not be regarded as an offer to sell or a solicitation of an offer to buy the products or securities to which it applies. No representation or warranty is given as to the accuracy or completeness of the information provided.

The information provided does not constitute investment advice nor take into account the individual financial circumstances or objectives of any investor. Any information that may be provided relating to past performance is not a reliable indicator of future results or performance.

To the extent permitted by law, in no event shall Capital.com (or any affiliate or employee) have any liability for any loss arising from the use of the information provided. Any person acting on the information does so entirely at their own risk.

Any information which could be construed as “investment research” has not been prepared in accordance with legal requirements designed to promote the independence of investment research and as such is considered to be a marketing communication.